Geron Stock Earnings Reports

Geron reported strong commercial momentum for RYTELO (imetelstat) in Q1 2026 with net revenue of $51.8 million, up 31% year-over-year and 8% sequentially. Management reiterated full-year 2026 net revenue guidance of $220M–$240M and total operating expense guidance of $230M–$240M, and expects a greater portion of revenue growth in the back half of the year. Key commercial initiatives focus on increasing awareness and earlier-line use in lower-risk MDS (primary U.S. opportunity ~8,000 second-line patients), targeted field and digital marketing, expanded medical affairs and investigator-sponsored studies, and building European commercialization options while protecting pricing integrity. The IMpactMF Phase III trial in relapsed/refractory myelofibrosis is fully enrolled with an interim overall survival analysis expected in the back half of 2026; management views a positive MF survival signal as supportive of imetelstat’s disease-modifying profile. Q1 operating expenses were $50.4M (down ~9% YoY) reflecting headcount reductions and disciplined spending; cash and securities were approximately $341M as of March 31, 2026, after expected seasonal payouts and CMC investments. Management emphasized financial discipline, continued investment in commercialization and supply chain, and that European commercialization decisions will be announced by year-end once pricing and market approach are clarified.